RemeGen (9995) Q2 2026 earnings summary

Executive summary

• Revenue surged 435.74% year-over-year to RMB5,850.2 million, driven by strong sales of telitacicept and disitamab vedotin, and a major licensing deal with AbbVie for RC148.

• Net profit reached RMB4,662.3 million, reversing a loss of RMB449.6 million in the prior year period.

• Significant pipeline progress with multiple regulatory approvals and clinical milestones for telitacicept and disitamab vedotin.

Financial highlights

• Gross profit was RMB5,581.3 million for the six months ended June 30, 2026.

• Research and development expenses decreased 36% year-over-year to RMB414.1 million.

• Selling and distribution expenses rose to RMB549.6 million, and administrative expenses increased to RMB262.4 million.

• Cash and cash equivalents stood at RMB1,528.9 million as of June 30, 2026.

• Gearing ratio improved to 15.6% from 50.2% at year-end 2025.

Outlook and guidance

• Plans to further commercialize telitacicept and disitamab vedotin and expand market presence in China.

• Continued acceleration of clinical trials and regulatory filings for pipeline products.

• Ongoing international collaborations with Vor Bio, Pfizer/Seagen, Santen China, and AbbVie to advance global clinical programs.